TURKU, Finland , May 18, 2022 /PRNewswire/ -- DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Anticancer Bioscience Ltd., an innovative China -base and international company pioneers in synthetic lethal approaches to precision oncology, today announced a notable collaboration pertaining to the development of silica-based long-acting controlled release treatments in oncology. The collaboration joins key European innovations in biomaterials and the pinnacle of Chinese drug research innovation emerging from the prestigious J. Michael Bishop Institute of Cancer Research, mentored by the year 1989 Noble prize winner Professor J. Michael Bishop .
While numerous therapies have shown significant promise in oncology, many still face difficult challenges that can be conveniently addressed by formulation technologies. While otherwise effective, shortcomings in solubility, bioavailability, pharmacokinetics paired with a narrow therapeutic index, practicality, side-effects and instability of the effective treatment can result in patients with life-threatening circumstances left with fewer treatment options.
Dr. Lasse Leino , CEO of DelSiTech, commented: "We are excited and proud to be collaborating with our innovative and forward-thinking partner in China to develop practical solutions to treat cancer patients world-wide. This new collaboration highlights the versatility of our Silica Matrix platform which is suitable for therapeutic applications in oncology. We estimate that in the future, many treatment modalities for cancer diseases will be centred on long-acting controlled release products. Recently, we presented data on how widely used anticancer peptides goserelin and triptorelin can be formulated into Silica Matrix to produce injectable long-acting products."
Dr. Dun Yang PhD, Founder, President, and CEO of Anticancer Bioscience, commented: "We are excited to be working with DelSiTech. The delivery of our cancer therapeutics using DelSiTech's proprietary drug delivery technology will enable us to explore novel mechanisms of action and new indications for our therapeutics. We recognize the need to partner with companies like DelSiTech who specialise in drug delivery, to maximize patient outcomes."
DelSiTech Ltd., located in Turku, Finland , is the leading technology specialist in biodegradable silica-based controlled release of small molecule drugs, biologics, and viral vectors. It develops and commercializes its proprietary, drug delivery technology in collaboration with a number of pharma and biotech companies to turn their ideas into novel drug products. For more information, see www.delsitech.com.
Silica Matrix is an advanced delivery technology platform for parenteral and local administration of injectable and implant dosage forms as well as eye drops. The proprietary technology is based on silica (SiO2) matrix into which the molecule or therapeutic agent of interest is embedded using a process called sol-gel. The resulting Silica Matrix is non-porous, biocompatible and it can be designed to biodegrade by matrix dissolution at the desired rate to ensure a tightly controlled release of the active substance over periods of days up to many months or a year.
Anticancer Bioscience (ACB) is an international private company, commercialising discoveries emerging from China's world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China . ACB is based on over 20 years of collaborative research between founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop . It has raised CNY131m (~USD21m ) and has operations in Chengdu, China , Hyderabad, India , San Francisco , USA , and St Andrews, UK.
What happened Shares of drugmaker Novavax (NASDAQ: NVAX) are up to the tune of 18.9% as of 2:11 p.m. ET Friday, according to data from S&P Global Market Intelligence, thanks to a confluence of events that work in the company's favor.
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) are down 53% as of 12:24 p.m. ET Friday, according to data from S&P Global Market Intelligence, following the release of disappointing results from a pivotal melanoma drug trial released Thursday evening. Iovance had already reported solid results for melanoma treatment Lifileucel in the middle of last year, ultimately finding a response rate of 36%. This follow-on study of cancer patients with advanced melanoma who had shown improvement after previously receiving and responding to anti-PD-1/L1 therapies isn't as encouraging, with an objective response rate of only 29%.
Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.
The company's protein-based shot has been authorized or approved in several other countries, including the U.K. and Singapore.
Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.
The White House on Thursday announced more steps to make the antiviral treatment Paxlovid more accessible across the U.S., cautioning that COVID-19 cases are likely to continue to climb over the summer travel season.
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week’s American Society of Clinical Oncology annual meeting. Arcellx Inc.’s (ACLX) stock jumped 11.9% after an abstract provided updated data for its CART-ddBCMA. SVB Securities analysts said in a note on Friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsed/refractory patients.”
Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced topline data from its Phase 1/2 trial of galinpepimut-S (GPS) in WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cancer. The trial evaluated SELLAS' peptide immunotherapeutic combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab). Data from 15 patients enrolled in the study has been preliminarily analyzed. Final data for all 17 patients is expected by the end of 2022. Related: Sellas Life Sciences Re
Wearables can provide key data to help individuals bolster their mental health, Whoop founder and CEO Will Ahmed recently told Yahoo Finance.
The Centers for Disease Control and Prevention have identified nine cases of Monkeypox in seven states. Dr. Mike joins "Good Day Philadelphia" to discuss.
Data from the latest test of lifileucel showed that a smaller share of patients responded to the drug, and that responses didn't last as long as in an earlier trial.
An investment climate that's suddenly turned chilly may leave promising companies out in the cold.
A Tokyo court began hearings Thursday in a lawsuit seeking nearly $5 million in damages for six people who were children in Fukushima at the time of its 2011 nuclear power plant disaster and later developed thyroid cancer. The plaintiffs are suing the operator of the nuclear plant, saying radiation released in the accident caused their illnesses. It is the first group lawsuit filed by Fukushima residents over health problems allegedly linked to the disaster, their lawyers say.
With Memorial Day near, many Americans are looking to fire up the grill. Just make sure you do it safely. Here are tips for cooking safely.
One of Greater Cincinnati's largest public companies will help other diagnostic businesses develop monkeypox tests.
A new CDC study found that one in five adult COVID-19 survivors has long COVID. Here's why, and what is actually considered long COVID.
CVS Health and Walmart will stop filling prescriptions for controlled substances ordered by clinicians working for Cerebral Inc. and Done Health, the broadest curbs yet by major pharmacies against the telehealth companies following scrutiny of their prescription practices. Cerebral had earlier disclosed the change to The Wall Street Journal.
The accelerator program uses Target’s scale to help under resourced founders with access, education and resources.
A lawsuit filed Thursday alleges long wait times at Larned State Hospital are unconstitutional and are causing mental and physical harm.